dark theme
hamburger menu
Chart & Data
Search a stock ticker below to get started.
MRK - $78.83
Merck & Company, Inc.
Yearly revenue growth: 20.09%
Yearly profit growth: 195.82%
Balance sheet (assets & liabs)
Institutional holders
Owner Share amount
The Vanguard Group, Inc. 199,765,856
BlackRock Fund Advisors 126,351,042
SSgA Funds Management, Inc. 115,536,595
Wellington Management Co. LLP 49,559,078
Geode Capital Management LLC 42,744,129
Northern Trust Investments, Inc.(... 31,027,928
Norges Bank Investment Management 27,515,487
Charles Schwab Investment Managem... 27,501,866
Massachusetts Financial Services ... 25,496,888
Franklin Advisers, Inc. 24,141,205
Merck & Company, Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linn...
Shareholder breakdown
general public